Literature DB >> 25453483

Glutaminase1 heterozygous mice show enhanced trace fear conditioning and Arc/Arg3.1 expression in hippocampus and cingulate cortex.

Liran Hazan1, Inna Gaisler-Salomon2.   

Abstract

Mice heterozygous for a mutation in the glutaminase (GLS1) gene (GLS1 HZ mice), with reduced glutamate recycling and release, display reduced hippocampal function as well as memory of contextual cues in a delay fear conditioning (FC) paradigm. Here, we asked whether this deficit reflects an inability to process contextual information or a selective alteration in salience attribution. In addition, we asked whether baseline and activity-induced hippocampal activity were diminished in GLS1 HZ mice. For this purpose, we manipulated the relative salience of the conditioned stimulus (CS) and contextual cues in FC tasks, and examined gene expression of the immediate early gene Arc (Arc/Arg3.1) in hippocampus and anterior cingulate cortex (ACC) following trace FC (tFC). The results indicate that GLS1 HZ mice succeed in processing contextual information when the salient CS is absent or less predictive. In addition, in the hippocampus-dependent tFC paradigm GLS1 HZ mice display enhanced CS learning. Furthermore, while baseline arc activation was reduced in GLS1 HZ mice in the hippocampus, in line with previous fMRI findings, it was enhanced in the hippocampus and anterior cingulate cortex following tFC. These findings suggest that GLS1 HZ mice have a pro-cognitive profile in the tFC paradigm, and this phenotype involves activation of both hippocampus and ACC. Taken together with previous work on the GLS1 HZ mouse, this study sheds light on the importance of glutamate transmission to memory processes that require the allocation of attentional resources, and extends our understanding of the underpinnings of attention deficits in SZ.
Copyright © 2014 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Keywords:  Anterior cingulate cortex; Arc/Arg 3.1; Fear conditioning; Glutamate; Glutaminase; Hippocampus; Mouse; Schizophrenia

Mesh:

Substances:

Year:  2014        PMID: 25453483     DOI: 10.1016/j.euroneuro.2014.10.003

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  4 in total

1.  Dopamine neuron dependent behaviors mediated by glutamate cotransmission.

Authors:  Susana Mingote; Nao Chuhma; Abigail Kalmbach; Gretchen M Thomsen; Yvonne Wang; Andra Mihali; Caroline Sferrazza; Ilana Zucker-Scharff; Anna-Claire Siena; Martha G Welch; José Lizardi-Ortiz; David Sulzer; Holly Moore; Inna Gaisler-Salomon; Stephen Rayport
Journal:  Elife       Date:  2017-07-13       Impact factor: 8.140

2.  Glutaminase activity in GLS1 Het mouse brain compared to putative pharmacological inhibition by ebselen using ex vivo MRS.

Authors:  Lauren Kosten; Golam M I Chowdhury; Susana Mingote; Steven Staelens; Douglas L Rothman; Kevin L Behar; Stephen Rayport
Journal:  Neurochem Int       Date:  2019-07-19       Impact factor: 3.921

3.  Glutamate Dehydrogenase-Deficient Mice Display Schizophrenia-Like Behavioral Abnormalities and CA1-Specific Hippocampal Dysfunction.

Authors:  Sharon S Lander; Usman Khan; Nicole Lewandowski; Darpan Chakraborty; Frank A Provenzano; Susana Mingote; Sergiy Chornyy; Francesca Frigerio; Pierre Maechler; Hanoch Kaphzan; Scott A Small; Stephen Rayport; Inna Gaisler-Salomon
Journal:  Schizophr Bull       Date:  2019-01-01       Impact factor: 9.306

4.  Genetic Pharmacotherapy as an Early CNS Drug Development Strategy: Testing Glutaminase Inhibition for Schizophrenia Treatment in Adult Mice.

Authors:  Susana Mingote; Justine Masson; Celia Gellman; Gretchen M Thomsen; Chyuan-Sheng Lin; Robert J Merker; Inna Gaisler-Salomon; Yvonne Wang; Rachel Ernst; René Hen; Stephen Rayport
Journal:  Front Syst Neurosci       Date:  2016-01-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.